The classical and alternative pathways of complement activation play distinct roles in spontaneous C3 fragment deposition and membrane attack complex (MAC) formation on human B lymphocytes

Immunology

Volumn 111, Issue 1, 2004, Pages 86-90

  Leslie, Robert Graham Quinton ^a   Nielsen, Claus Henrik ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; COMPLEMENT MEMBRANE ATTACK COMPLEX; IMMUNOGLOBULIN FRAGMENT;

ARTICLE; B LYMPHOCYTE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN DEPOSITION; INCUBATION TIME; MEDICAL ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ACETYLGLUCOSAMINE; ANIMALS; ANTICOAGULANTS; B-LYMPHOCYTES; CELLS, CULTURED; COMPLEMENT C3; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; EDETIC ACID; HUMANS; ISOANTIBODIES; MANNOSE; RABBITS;

EID: 0347126484     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2004.01780.x     Document Type: Article

References (18)

1. Marquart HV, Svehag S-E, Leslie RGQ. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes. J Immunol 1994; 153:307-15.
2. Nielsen CH, Marquart HV, Prodinger WM, Leslie RGQ. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on the human B lymphocyte surface. Immunology 2001; 104:418-22.
3. Nielsen CH, Pedersen ML, Marquart HV, Prodinger WM, Leslie RGQ. The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and MAC formation on normal peripheral human B lymphocytes. Eur J Immunol 2002; 32:1359-67.
4. Mold C, Nemerow GR, Bradt BM, Cooper NR. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells. J Immunol 1988; 140: 1923-9.
5. Schwendinger MG, Spruth M, Schoch J, Dierich MP, Prodinger WM. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3-fragments on CR2-expressing homologous cells. J Immunol 1997; 158:5455-63.
6. Leslie RGQ. The influence of complement receptor type 1 (CD35) and decay accelerating factor (CD55) on complement receptor type 2 (CD21) -mediated alternative pathway activation by B lymphocytes. Immunology 1999; 97:371-3.
7. Leslie RGQ, Prodinger WM, Nielsen CH. Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of the hydrolysed form of complement factor 3 (C3I) to human B lymphocytes. Eur J Immunol 2003; 33:3311-21.
8. Olesen E, Johnson AA, Damgaard G, Leslie RGQ. The Requirement of localised, CR2-mediated alternative pathway (AP) activation of complement for covalent deposition of C3 fragments on normal B lymphocytes. Immunology 1998; 93:177-83.
9. Ross GD, Lambris JD, Cain JA, Newman SL. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs. CR1 cofactor activity. J Immunol 1982; 129:2051-60.
10. Weis WL, Drickamer K, Hendrickson WA. Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature 1992; 360:127-34.
11. Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, Ichikawa N, Nakata M, Mizuochi T. A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin. J Biol Chem 1996; 271:2448-54.
12. Mollnes TE, Lea T, Harboe M, Tschopp J. Monoclonal antibodies recognising a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 1985; 22:183-95.
13. Marquart HV, Olesen EH, Johnson AA, Damgaard G, Leslie RGQ. A comparative study of normal B cells and the EBV-positive Burkitt's lymphoma cell line, Raji, as activators of the complement system. Scand J Immunol 1997; 46:246-53.
14. Klickstein LB, Bartow TJ, Miletic V, Rabson LD, Smith JA, Fearon DT. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med 1988; 168:1699-717.
15. Füst G, Erdei A, Sármay G, Medgyesi GA, Gergely J. Functionally active C1 on the surface of human peripheral lymphocytes, its role in the complement-mediated inhibition of Fc receptors on B lymphocytes. Clin Immunol Immunopathol 1976; 5:377-87.
16. Kerekes K, Prechl J, Bajtay Z, Mihály J, Erdei A. A further link between innate and adaptive immunity: C3 deposition on antigen-presenting cells enhances the proliferation of antigen-specific T cells. Internat Immunol 1998; 10:1923-30.
17. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ T cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003; 421:388-92.
18. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Nature 1992; 258:1156-9.